Developer docs
API playgroundTry for free, no card

Search company profiles

Ardelyx

Full company profile

uuid0002ni2

Namestring
Ardelyx
Legal namestring
Ardelyx, Inc.
Websiteurl
ardelyx.com
Company typeenum
Public
Founded yearint
2009
Descriptiontext

Ardelyx, Inc. (NASDAQ: ARDX) is a commercial-stage biopharmaceutical company headquartered in Waltham, Massachusetts that develops novel oral therapeutics based on its proprietary NHE3 (sodium-hydrogen exchanger 3) inhibitor platform. Founded in 2007 and led by President and CEO Mike Raab since 2009, Ardelyx has commercialized two FDA-approved first-in-class products containing the active ingredient tenapanor: IBSRELA, approved for irritable bowel syndrome with constipation (IBS-C) in adults, and XPHOZAH, the first and only FDA-approved phosphate absorption inhibitor for chronic kidney disease patients on dialysis with hyperphosphatemia. The company's pipeline includes RDX10531, a next-generation NHE3 inhibitor in preclinical development, plus Phase 3 trials expanding tenapanor into chronic idiopathic constipation and pediatric IBS-C populations.

The company generates revenue primarily through direct U.S. product sales of IBSRELA and XPHOZAH, supported by a specialty sales force targeting gastroenterologists, nephrologists, and primary care physicians, complemented by patient services through ArdelyxAssist. International revenue is sourced through licensing and royalty arrangements with Kyowa Kirin for Japan (where tenapanor is marketed as PHOZEVEL for hyperphosphatemia) and Shanghai Fosun Pharmaceutical for China (marketed as Wan Ti Le). Total 2025 product revenue was approximately $407 million (with IBSRELA at $274M growing 73% year-over-year and XPHOZAH at $103.6M), and Q1 2026 revenue reached $93.4 million (+38% year-over-year), with management guiding to $520–550M for full-year 2026 and targeting $1 billion in annual IBSRELA revenue by 2029. Patent protection for tenapanor formulations extends through November 2042 following a recent patent extension, and the company is publicly listed on NASDAQ with a market capitalization of approximately $1.58 billion as of April 2026.

Short descriptiontext

Ardelyx is a commercial-stage biopharmaceutical company that develops and markets two FDA-approved first-in-class NHE3 inhibitor drugs—IBSRELA for IBS-C and XPHOZAH for hyperphosphatemia in dialysis patients—generating over $400M in 2025 revenue and pursuing pipeline expansion in additional indications and international markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, gastroenterology therapeutics, nephrology therapeutics, phosphate absorption inhibitors, NHE3 inhibitor platform
Industry2 codes
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAI
Rare Renal & Nephrology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceuticals (Gastroenterology and Nephrology)
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Product Sales - IBSRELA
TypeOne Time License
Description

Revenue from direct product sales of IBSRELA (tenapanor) for irritable bowel syndrome with constipation (IBS-C) in the United States. IBSRELA generated $274 million in 2025 revenue, up 73% year-over-year, with Q1 2026 revenue of $70.1 million up 58% YoY.

fool.com
2Product Sales - XPHOZAH
TypeOne Time License
Description

Revenue from direct product sales of XPHOZAH (tenapanor) for chronic kidney disease with hyperphosphatemia in the United States. XPHOZAH generated $103.6 million in 2025 revenue, though facing headwinds from Medicare Part D reimbursement changes.

fool.com
3Licensing/Royalties - Japan (Kyowa Kirin)
TypeLicensing Royalties
Description

Royalty and milestone payments from Kyowa Kirin collaboration for tenapanor in Japan, where it is marketed as PHOZEVEL. Includes upfront payments, regulatory approval milestones, sales targets, and future royalties.

prnewswire.com
4Licensing/Royalties - China (Fosun)
TypeLicensing Royalties
Description

Exclusive license agreement with Shanghai Fosun Pharmaceutical for development and commercialization of tenapanor for IBS-C and hyperphosphatemia in China, where it is marketed as Wan Ti Le.

ardelyx.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1IBSRELA
Description

FDA-approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, containing tenapanor as the active ingredient.

ardelyx.com
+2 more records
Core offering1 text field

Ardelyx is a commercial-stage biopharmaceutical company that develops and sells FDA-approved oral therapeutics based on its proprietary NHE3 inhibitor platform. Its two marketed products, IBSRELA (tenapanor) for irritable bowel syndrome with constipation (IBS-C) in adults and XPHOZAH (tenapanor) for hyperphosphatemia in chronic kidney disease patients on dialysis, are sold directly to U.S. prescribers through its own sales force and specialty distribution, while ex-U.S. rights are licensed to Kyowa Kirin (Japan) and Shanghai Fosun Pharmaceutical (China). The company also operates ArdelyxAssist, a patient access and affordability services program supporting its products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 73% year-over-year revenue growth for IBSRELA in 2025
+3 more records
Product overview1 text field

Ardelyx is a commercial-stage biopharmaceutical company that has developed and commercialized two FDA-approved first-in-class medications: IBSRELA (tenapanor) for irritable bowel syndrome with constipation (IBS-C) and XPHOZAH (tenapanor) for hyperphosphatemia in chronic kidney disease patients on dialysis. Both products share the same active ingredient (tenapanor) but target different indications through the same NHE3 inhibition mechanism. The company supports its products through ArdelyxAssist, a patient services program offering access and affordability support. Ardelyx's pipeline includes RDX10531 (a next-generation NHE3 inhibitor) and multiple Phase 3 clinical trials expanding tenapanor into pediatric IBS-C and chronic idiopathic constipation indications.

Product and service4 records
1IBSRELA (tenapanor)
CategoryPrescription pharmaceutical (gastroenterology)
Description

FDA-approved oral medication for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. It is a first-in-class NHE3 (sodium-hydrogen exchanger 3) inhibitor that works by decreasing phosphate absorption through the gastrointestinal tract, providing rapid and sustained symptom relief.

2XPHOZAH (tenapanor)
CategoryPrescription pharmaceutical (nephrology)
Description

FDA-approved oral phosphate absorption inhibitor for adults with chronic kidney disease on dialysis who have inadequate response to phosphate binders, for serum phosphorus control. First and only FDA-approved therapy in its class for this indication, leveraging the same NHE3 inhibitor mechanism as IBSRELA.

3ArdelyxAssist
CategoryPatient services / patient access program
Description

Innovative, digital-forward, high-touch patient services program providing access and affordability support for patients prescribed Ardelyx medicines, including copay assistance for eligible commercially insured patients, free medication programs for those who qualify, and insurance support services.

4RDX10531
CategoryPipeline candidate (preclinical)
Description

Next-generation NHE3 inhibitor in preclinical development with potential application across multiple therapeutic areas.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierFlagshipTypeGTM or Marketing PartnerAnnounced on2026-02-24
Description

Multi-year partnership naming Ardelyx as official corporate pharmaceutical Marketing Partner of the LPGA Tour to break stigma around digestive health issues, particularly IBS-C affecting over 90% of women. Includes digital content, player ambassadors, and custom storytelling across LPGA platforms.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic collaboration for development and commercialization of tenapanor for cardiorenal diseases including hyperphosphatemia in Japan. Tenapanor is approved and marketed as PHOZEVEL for improvement of hyperphosphatemia in adult CKD patients on dialysis in Japan.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Exclusive license agreement for development and commercialization of tenapanor for IBS-C and hyperphosphatemia in China. Tenapanor is approved and marketed under the Chinese trade name Wan Ti Le for patients with CKD on hemodialysis with hyperphosphatemia.

Strategic tierMinorTypeOthers
Description

Member of industry organization supporting innovation and improving patient outcomes in Massachusetts.

Strategic tierMinorTypeOthers
Description

Member of California life sciences industry organization.

Strategic tierMinorTypeOthers
Description

Member of Texas healthcare and bioscience industry organization.

7BIO (California and Pennsylvania Affiliates)
Strategic tierMinorTypeOthers
Description

Member of BIO industry organization affiliates in California and Pennsylvania.

ardelyx.com
8Life Science Cares Boston
Strategic tierMinorTypeOthers
Description

Community partnership through industry-wide effort pooling resources and volunteer hours to support nonprofits in the Boston area.

ardelyx.com
9Life Science Cares Bay Area
Strategic tierMinorTypeOthers
Description

Community partnership supporting nonprofits in the Bay Area through pooled industry resources and volunteer efforts.

ardelyx.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

AstraZeneca markets FARXIGA (dapagliflozin), a leading CKD and cardiorenal therapy, and through its Alexion rare disease unit competes in adjacent nephrology indications; Ardelyx chairman David Mott previously led MedImmune's $15.6B sale to AstraZeneca, highlighting the strategic overlap.

2Shield Therapeutics
TypeEmerging player
Description

Shield Therapeutics markets ACCRUFeR (ferric maltol), an oral iron therapy for iron deficiency in CKD, addressing the same dialysis and CKD patient population as XPHOZAH but for a different comorbidity, making it a partial overlap.

TypeDirect peer
Description

Travere is a commercial-stage biopharma focused on rare kidney diseases, with FDA-approved therapies (FILSPARI, sparsentan for IgAN) targeting the same nephrology specialist channel that Ardelyx relies on for XPHOZAH, and overlapping investor audience in renal therapeutics.

TypeBroad incumbent
Description

Amgen is a major nephrology/cardiorenal player (EPOGEN, Repatha, Tezspire partnerships) with broad hospital and nephrologist relationships, and via its Horizon Therapeutics acquisition has overlapping rare disease infrastructure relevant to the XPHOZAH launch.

TypeEmerging player
Description

Cara Therapeutics is an emerging biopharma developing therapies for chronic kidney disease-associated pruritus (KORSUVA), sharing the dialysis patient population and nephrology channel that XPHOZAH targets, but with a different symptom focus.

TypeDirect peer
Description

Ironwood markets LINZESS (linaclotide), the leading prescribed therapy for IBS-C and chronic idiopathic constipation in the U.S., making it the most direct head-to-head competitor to IBSRELA in the same patient population and prescriber base (gastroenterologists).

TypeBroad incumbent
Description

AbbVie holds U.S. co-marketing rights to LINZESS (with Ironwood), giving it direct exposure to the IBS-C market Ardelyx targets, alongside a much broader immunology, oncology and neuroscience portfolio that dwarfs Ardelyx in scale.

TypeBroad incumbent
Description

Takeda owns AMITIZA (lubiprostone), a competing chronic constipation/IBS-C therapy, and through its broader rare disease and GI portfolio competes in adjacent specialty pharmacy channels relevant to Ardelyx.

TypeRegional player
Description

Vifor Pharma (a CSL Vifor subsidiary) is a Switzerland-based leader in iron deficiency and nephrology therapies (including intravenous iron and phosphate binders), serving as a global, non-U.S.-dominant renal therapeutics competitor relevant to Ardelyx's international tenapanor expansion.

TypeDirect peer
Description

Salix (a Bausch Health gastroenterology-focused specialty business) markets multiple GI therapies including rifaximin and targets the same gastroenterologist prescriber base as IBSRELA, with overlapping sales infrastructure and access/reimbursement expertise.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks3 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ardelyx

Specialty Pharmaceuticals (Gastroenterology and Nephrology)ardelyx.com

Ardelyx is a commercial-stage biopharmaceutical company that develops and markets two FDA-approved first-in-class NHE3 inhibitor drugs—IBSRELA for IBS-C and XPHOZAH for hyperphosphatemia in dialysis patients—generating over $400M in 2025 revenue and pursuing pipeline expansion in additional indications and international markets.

What Ardelyx does

Ardelyx, Inc. (NASDAQ: ARDX) is a commercial-stage biopharmaceutical company headquartered in Waltham, Massachusetts that develops novel oral therapeutics based on its proprietary NHE3 (sodium-hydrogen exchanger 3) inhibitor platform. Founded in 2007 and led by President and CEO Mike Raab since 2009, Ardelyx has commercialized two FDA-approved first-in-class products containing the active ingredient tenapanor: IBSRELA, approved for irritable bowel syndrome with constipation (IBS-C) in adults, and XPHOZAH, the first and only FDA-approved phosphate absorption inhibitor for chronic kidney disease patients on dialysis with hyperphosphatemia. The company's pipeline includes RDX10531, a next-generation NHE3 inhibitor in preclinical development, plus Phase 3 trials expanding tenapanor into chronic idiopathic constipation and pediatric IBS-C populations.

The company generates revenue primarily through direct U.S. product sales of IBSRELA and XPHOZAH, supported by a specialty sales force targeting gastroenterologists, nephrologists, and primary care physicians, complemented by patient services through ArdelyxAssist. International revenue is sourced through licensing and royalty arrangements with Kyowa Kirin for Japan (where tenapanor is marketed as PHOZEVEL for hyperphosphatemia) and Shanghai Fosun Pharmaceutical for China (marketed as Wan Ti Le). Total 2025 product revenue was approximately $407 million (with IBSRELA at $274M growing 73% year-over-year and XPHOZAH at $103.6M), and Q1 2026 revenue reached $93.4 million (+38% year-over-year), with management guiding to $520–550M for full-year 2026 and targeting $1 billion in annual IBSRELA revenue by 2029. Patent protection for tenapanor formulations extends through November 2042 following a recent patent extension, and the company is publicly listed on NASDAQ with a market capitalization of approximately $1.58 billion as of April 2026.

Ardelyx firmographics

Firmographics
Name
Ardelyx
Legal name
Ardelyx, Inc.
Website
https://ardelyx.com
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Ardelyx is a commercial-stage biopharmaceutical company that develops and markets two FDA-approved first-in-class NHE3 inhibitor drugs—IBSRELA for IBS-C and XPHOZAH for hyperphosphatemia in dialysis patients—generating over $400M in 2025 revenue and pursuing pipeline expansion in additional indications and international markets.
Ownership category
akta.pro rank

Ardelyx industry classification

Industry
Product category
Specialty Pharmaceuticals (Gastroenterology and Nephrology)
NAICS
Medicinal and Botanical Manufacturing (325411)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAI
Rare Renal & Nephrology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Gastroenterology therapeutics
  • Nephrology therapeutics
  • Phosphate absorption inhibitors
  • NHE3 inhibitor platform

Where Ardelyx is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Ardelyx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Product Sales - IBSRELA: Revenue from direct product sales of IBSRELA (tenapanor) for irritable bowel syndrome with constipation (IBS-C) in the United States. IBSRELA generated $274 million in 2025 revenue, up 73% year-over-year, with Q1 2026 revenue of $70.1 million up 58% YoY.
  2. Product Sales - XPHOZAH: Revenue from direct product sales of XPHOZAH (tenapanor) for chronic kidney disease with hyperphosphatemia in the United States. XPHOZAH generated $103.6 million in 2025 revenue, though facing headwinds from Medicare Part D reimbursement changes.
  3. Licensing/Royalties - Japan (Kyowa Kirin): Royalty and milestone payments from Kyowa Kirin collaboration for tenapanor in Japan, where it is marketed as PHOZEVEL. Includes upfront payments, regulatory approval milestones, sales targets, and future royalties.
  4. Licensing/Royalties - China (Fosun): Exclusive license agreement with Shanghai Fosun Pharmaceutical for development and commercialization of tenapanor for IBS-C and hyperphosphatemia in China, where it is marketed as Wan Ti Le.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Ardelyx product offering

Product offering

Core offering

Ardelyx is a commercial-stage biopharmaceutical company that develops and sells FDA-approved oral therapeutics based on its proprietary NHE3 inhibitor platform. Its two marketed products, IBSRELA (tenapanor) for irritable bowel syndrome with constipation (IBS-C) in adults and XPHOZAH (tenapanor) for hyperphosphatemia in chronic kidney disease patients on dialysis, are sold directly to U.S. prescribers through its own sales force and specialty distribution, while ex-U.S. rights are licensed to Kyowa Kirin (Japan) and Shanghai Fosun Pharmaceutical (China). The company also operates ArdelyxAssist, a patient access and affordability services program supporting its products.

Product overview

Ardelyx is a commercial-stage biopharmaceutical company that has developed and commercialized two FDA-approved first-in-class medications: IBSRELA (tenapanor) for irritable bowel syndrome with constipation (IBS-C) and XPHOZAH (tenapanor) for hyperphosphatemia in chronic kidney disease patients on dialysis. Both products share the same active ingredient (tenapanor) but target different indications through the same NHE3 inhibition mechanism. The company supports its products through ArdelyxAssist, a patient services program offering access and affordability support. Ardelyx's pipeline includes RDX10531 (a next-generation NHE3 inhibitor) and multiple Phase 3 clinical trials expanding tenapanor into pediatric IBS-C and chronic idiopathic constipation indications.

Differentiator

Problem solved

Functional benefit

Brands

  • IBSRELA: FDA-approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, containing tenapanor as the active ingredient.
  • XPHOZAH
  • ArdelyxAssist

Products and services

  • IBSRELA (tenapanor) FDA-approved oral medication for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. It is a first-in-class NHE3 (sodium-hydrogen exchanger 3) inhibitor that works by decreasing phosphate absorption through the gastrointestinal tract, providing rapid and sustained symptom relief.
  • XPHOZAH (tenapanor) FDA-approved oral phosphate absorption inhibitor for adults with chronic kidney disease on dialysis who have inadequate response to phosphate binders, for serum phosphorus control. First and only FDA-approved therapy in its class for this indication, leveraging the same NHE3 inhibitor mechanism as IBSRELA.
  • ArdelyxAssist Innovative, digital-forward, high-touch patient services program providing access and affordability support for patients prescribed Ardelyx medicines, including copay assistance for eligible commercially insured patients, free medication programs for those who qualify, and insurance support services.
  • RDX10531 Next-generation NHE3 inhibitor in preclinical development with potential application across multiple therapeutic areas.

Quantifiable outcome

  • 73% year-over-year revenue growth for IBSRELA in 2025
  • +3 more outcomes

Companies that use Ardelyx

Customer profile

Segments4 records

Ideal customer profiles3 records

Ardelyx technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Ardelyx partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered flagship, core and minor.

  • Ladies Professional Golf Association (LPGA)flagshipGTM or Marketing Partner · 24 February 2026Multi-year partnership naming Ardelyx as official corporate pharmaceutical Marketing Partner of the LPGA Tour to break stigma around digestive health issues, particularly IBS-C affecting over 90% of women. Includes digital content, player ambassadors, and custom storytelling across LPGA platforms.
  • Kyowa Kirin Co. Ltd.coreStrategic or Co-development PartnerStrategic collaboration for development and commercialization of tenapanor for cardiorenal diseases including hyperphosphatemia in Japan. Tenapanor is approved and marketed as PHOZEVEL for improvement of hyperphosphatemia in adult CKD patients on dialysis in Japan.
  • Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.coreStrategic or Co-development PartnerExclusive license agreement for development and commercialization of tenapanor for IBS-C and hyperphosphatemia in China. Tenapanor is approved and marketed under the Chinese trade name Wan Ti Le for patients with CKD on hemodialysis with hyperphosphatemia.
  • MassBiominorOthersMember of industry organization supporting innovation and improving patient outcomes in Massachusetts.
  • California Life SciencesminorOthersMember of California life sciences industry organization.
  • Texas Healthcare and Bioscience InstituteminorOthersMember of Texas healthcare and bioscience industry organization.
  • BIO (California and Pennsylvania Affiliates)minorOthersMember of BIO industry organization affiliates in California and Pennsylvania.
  • Life Science Cares BostonminorOthersCommunity partnership through industry-wide effort pooling resources and volunteer hours to support nonprofits in the Boston area.
  • Life Science Cares Bay AreaminorOthersCommunity partnership supporting nonprofits in the Bay Area through pooled industry resources and volunteer efforts.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Ardelyx competitors and assessment

Company assessment

Broad incumbents

  • AstraZeneca: AstraZeneca markets FARXIGA (dapagliflozin), a leading CKD and cardiorenal therapy, and through its Alexion rare disease unit competes in adjacent nephrology indications; Ardelyx chairman David Mott previously led MedImmune's $15.6B sale to AstraZeneca, highlighting the strategic overlap.
  • Amgen: Amgen is a major nephrology/cardiorenal player (EPOGEN, Repatha, Tezspire partnerships) with broad hospital and nephrologist relationships, and via its Horizon Therapeutics acquisition has overlapping rare disease infrastructure relevant to the XPHOZAH launch.
  • AbbVie: AbbVie holds U.S. co-marketing rights to LINZESS (with Ironwood), giving it direct exposure to the IBS-C market Ardelyx targets, alongside a much broader immunology, oncology and neuroscience portfolio that dwarfs Ardelyx in scale.
  • Takeda Pharmaceutical: Takeda owns AMITIZA (lubiprostone), a competing chronic constipation/IBS-C therapy, and through its broader rare disease and GI portfolio competes in adjacent specialty pharmacy channels relevant to Ardelyx.

Emerging players

  • Shield Therapeutics: Shield Therapeutics markets ACCRUFeR (ferric maltol), an oral iron therapy for iron deficiency in CKD, addressing the same dialysis and CKD patient population as XPHOZAH but for a different comorbidity, making it a partial overlap.
  • Cara Therapeutics: Cara Therapeutics is an emerging biopharma developing therapies for chronic kidney disease-associated pruritus (KORSUVA), sharing the dialysis patient population and nephrology channel that XPHOZAH targets, but with a different symptom focus.

Direct peers

  • Travere Therapeutics: Travere is a commercial-stage biopharma focused on rare kidney diseases, with FDA-approved therapies (FILSPARI, sparsentan for IgAN) targeting the same nephrology specialist channel that Ardelyx relies on for XPHOZAH, and overlapping investor audience in renal therapeutics.
  • Ironwood Pharmaceuticals: Ironwood markets LINZESS (linaclotide), the leading prescribed therapy for IBS-C and chronic idiopathic constipation in the U.S., making it the most direct head-to-head competitor to IBSRELA in the same patient population and prescriber base (gastroenterologists).
  • Salix Pharmaceuticals: Salix (a Bausch Health gastroenterology-focused specialty business) markets multiple GI therapies including rifaximin and targets the same gastroenterologist prescriber base as IBSRELA, with overlapping sales infrastructure and access/reimbursement expertise.

Regional players

  • Vifor Pharma: Vifor Pharma (a CSL Vifor subsidiary) is a Switzerland-based leader in iron deficiency and nephrology therapies (including intravenous iron and phosphate binders), serving as a global, non-U.S.-dominant renal therapeutics competitor relevant to Ardelyx's international tenapanor expansion.

Market position

Strengths5 records

Competitive moat4 records

Key risks3 records

Key highlights7 records

Customer concentration

Ardelyx social profiles

Digital presence

Ardelyx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ardelyx leadership team

Management profile

Number of profiles

Profiles16 records

Ardelyx funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ardelyx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ardelyx

What does Ardelyx do?

Ardelyx is a commercial-stage biopharmaceutical company that develops and sells FDA-approved oral therapeutics based on its proprietary NHE3 inhibitor platform. Its two marketed products, IBSRELA (tenapanor) for irritable bowel syndrome with constipation (IBS-C) in adults and XPHOZAH (tenapanor) for hyperphosphatemia in chronic kidney disease patients on dialysis, are sold directly to U.S. prescribers through its own sales force and specialty distribution, while ex-U.S. rights are licensed to Kyowa Kirin (Japan) and Shanghai Fosun Pharmaceutical (China). The company also operates ArdelyxAssist, a patient access and affordability services program supporting its products.

Is Ardelyx a public or private company?

Ardelyx is a public company. It is classified as public and is currently operating.

When was Ardelyx founded?

Ardelyx was founded in 2009. It employs 501 to 1,000 people.

Where is Ardelyx based?

Ardelyx is headquartered in Waltham, United States, in the North America region.

How does Ardelyx make money?

Four revenue lines are on record. Product Sales - IBSRELA is the primary driver. The others are product Sales - XPHOZAH, licensing/Royalties - Japan (Kyowa Kirin) and licensing/Royalties - China (Fosun).

Who are Ardelyx's main competitors?

Broad incumbents on record are AstraZeneca, Amgen, AbbVie and Takeda Pharmaceutical. Emerging players are Shield Therapeutics and Cara Therapeutics. Direct peers are Travere Therapeutics, Ironwood Pharmaceuticals and Salix Pharmaceuticals. Vifor Pharma is listed as a regional player.

Does Ardelyx have an API?

No public API is recorded for Ardelyx.

What industry is Ardelyx in?

Ardelyx's product category is Specialty Pharmaceuticals (Gastroenterology and Nephrology). Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of HLAIAIAI, Rare Renal & Nephrology Disorder Therapies. Its NAICS code is 325411 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireArdelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ARDXDJS Law Group announced a securities class action against Ardelyx, Inc. for alleged false and misleading statements under the Securities Exchange Act. The class period runs from January 13, 2025 to August 6, 2026, with a November 16, 2026 deadline. Shareholders are encouraged to contact the firm for possible lead plaintiff appointments.Simply Wall StArdelyx (ARDX) Stock May Trade At A Discount On Trial ProgressArdelyx's stock has gained 231.7% over five years, but its P/S ratio of 1.7x is below the sector's 10.2x, suggesting undervaluation. The company reported 19% Q3 product revenue growth and progress on IBSRELA trials, which could justify a higher multiple.AktienARDX DEADLINE TODAY: ROSEN, A LONGSTANDING LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important November 16 Deadline in Securities Class Action - ARDXRosen Law Firm urges Ardelyx investors who bought stock between January 13, 2025 and August 6, 2026 to secure counsel before the November 16, 2026 lead-plaintiff deadline in a securities class action. The lawsuit alleges false statements about XPHOZAH and IBSRELA's commercial performance and growth prospects. No class has been certified yet.FinancialContent Business PageARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS LawSchall, Brown & Schwartz LLP is reminding Ardelyx shareholders of a securities fraud class action alleging false statements about reimbursement barriers affecting XPHOZAH and IBSRELA. The class period runs from January 13, 2025 to August 6, 2026, with a November 16, 2026 deadline for lead plaintiff appointment.PR NewswireARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS LawSchall, Brown & Schwartz LLP announced a securities fraud class action against Ardelyx, Inc. for alleged false statements about reimbursement barriers affecting XPHOZAH and IBSRELA. The class period runs from January 13, 2025 to August 6, 2026, with a November 16, 2026 deadline for lead plaintiff appointments.The future of tradingARDX DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important November 16 Deadline in Securities Class Action - ARDXRosen Law Firm reminds Ardelyx investors of a November 16, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges false statements about XPHOZAH and IBSRELA's commercial performance and growth prospects. Investors may seek compensation without out-of-pocket fees.GlobeNewswireARDX DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important November 16 Deadline in Securities Class Action - ARDXRosen Law Firm urges Ardelyx investors who bought stock between Jan 13, 2025 and Aug 6, 2026 to file for lead plaintiff by Nov 16, 2026. The firm claims the lawsuit alleges false statements about XPHOZAH and IBSRELA's commercial performance and growth prospects. No class has been certified yet.The future of tradingPomerantz LLP Notifies Shareholders of Class Action Lawsuit Against Ardelyx, Inc. – ARDXPomerantz LLP notified shareholders of a class action lawsuit against Ardelyx, Inc., alleging securities fraud. Ardelyx had cut its 2026 IBSRELA revenue guidance and withdrawn XPHOZAH guidance, causing its stock to fall 17.86% to $4.00. Shareholders have until November 16, 2026, to seek lead plaintiff appointment.Business & FinancialARDX DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors To Secure Counsel Before Important November 16 Deadline In Securities Class Action - ARDXRosen Law Firm reminds Ardelyx investors of a November 16, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges false statements about XPHOZAH and IBSRELA's commercial performance and reimbursement barriers. Investors may seek compensation via contingency fee arrangement.The future of tradingARDX DEADLINE: ROSEN, GLOBAL INVESTOR RIGHTS COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important November 16 Deadline in Securities Class Action - ARDXRosen Law Firm reminds Ardelyx investors of a November 16, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges false statements about XPHOZAH and IBSRELA's commercial performance and growth prospects. Investors may join the class action without out-of-pocket fees.